Molecular markers for determining the risk of very early gastric cancer and evaluating the risk of progression of precancerous lesions of gastric cancer and their application in diagnostic kits

A combination of KLK10, KRT7, and LAMC2 markers, with monoclonal antibodies, addresses the challenge of early gastric cancer diagnosis by accurately predicting the progression from precancerous lesions, achieving high prediction accuracy and enabling timely therapeutic interventions.

JP2024541220AActive Publication Date: 2024-11-08TSINGHUA UNIVERSITY
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
JP2024524380
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-10-24
Filing Date
2022-04-04
Publication Date
2024-11-08
Estimated Expiration
2042-04-04

AI Technical Summary

Technical Problem

Existing technologies face challenges in accurately determining the risk of progression from precancerous lesions to gastric cancer and other gastrointestinal tumors, particularly due to the long timeframe and difficulty in identifying the critical transition point from gastritis to cancer.

Method used

A combination of molecular markers, including KLK10, KRT7, and LAMC2, is used to detect the expression levels of very early gastric cancer cells, accompanied by monoclonal antibodies for specific detection, enabling the development of diagnostic kits and systems to assess the risk of progression from low-grade dysplasia to gastric cancer and other gastrointestinal tumors.

Benefits of technology

The marker combination allows for accurate assessment of the risk of progression to gastric cancer, enabling early diagnosis and therapeutic interventions, with a prediction accuracy of up to 96% and a 12-month advance in diagnosis, independent of clinical indicators like age and Helicobacter pylori infection.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024541220000001_ABST
    Figure 2024541220000001_ABST
Patent Text Reader

Abstract

Based on previous research (CN202080001970.7), the inventor further discovered molecular markers (KRT7, KLK10, LAMC2) that specifically label ultra-early stage gastric cancer cells, prepared marker monoclonal antibodies, and applied them to prepare a kit for assessing the risk of ultra-early stage gastric cancer and other digestive tumors based on gastric tissue or blood. Implementation of the markers in a multi-institutional sequential cohort of 318 patients showed that: 1) the overall predictive accuracy of progression risk of low-grade dysplasia was 86%, with an AUC value of 0.87; 2) the accuracy was closely related to the time of progression of low-grade dysplasia, with an accuracy increasing to 95% 6 months before gastric cancer occurrence, which could advance the time of early diagnosis of gastric cancer by an average of 10 months; and: 3) the diagnostic accuracy of the markers for early gastric cancer exceeded 97%. The marker can also be used to determine the risk of postoperative recurrence of gastric cancer. The present invention can be used to evaluate the risk of very early onset of gastric cancer and other digestive tumors, and can also be used as an intervention index for very early prevention and treatment of the above-mentioned digestive tumors, and has good prospects for application.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a combination of markers and a measurement system thereof that assist in determining the risk of very early onset of gastric cancer and other digestive tract tumors and assess the risk of progression of precancerous gastric lesions such as low-grade dysplasia. [Background technology]

[0002] The significance of early diagnosis of gastric cancer is great. Intestinal gastric cancer is the main subtype of gastric cancer, and its development is through a series of precancerous lesion processes such as dysplasia. Evaluating the risk of progression from precancerous lesions to gastric cancer and realizing ultra-early diagnosis of gastric cancer is of great significance for the prevention and treatment of gastric cancer.

[0003] Because gastritis carcinogenesis takes a long time, it is difficult to determine the key turning point of gastritis carcinogenesis, i.e., the "starting point of carcinogenesis," which is a major obstacle to ultra-early diagnosis of gastric cancer. The inventors have created the world's first single-cell atlas of gastritis carcinogenesis in advance, and discovered a group of ultra-early gastric cancer cells that begin to appear at the low-grade dysplasia stage of the stomach and have a high risk of carcinogenesis, and have used this type of cell as a marker for ultra-early gastric cancer diagnosis [1][2]. Discovering the molecular characteristics of ultra-early gastric cancer cells and building a diagnostic system that specifically identifies ultra-early gastric cancer cells is promising for accurate evaluation of the progression risk of gastric precancerous lesions such as dysplasia and for the realization of ultra-early gastric cancer diagnosis.

[0004] Tumors in other organs of the digestive system, such as the intestine, esophagus, and pancreas, also develop through a series of precancerous lesions. Using molecular features associated with very early gastric cancer cells as a common means of establishing very early diagnosis of digestive system cancer, and is also of great significance for the prevention and treatment of digestive system tumors. Summary of the Invention

[0005] The present invention provides an application of a reagent for detecting the expression level of a combination of gastric cancer very early cell marker molecules (including KLK10, KRT7 and LAMC2) for assessing the risk of progression from low-grade dysplasia to gastric cancer and determining the risk of very early gastric cancer. Among them, the combination of markers includes KRT7, KLK10 and LAMC2. In the present invention, the cells labeled with the above-mentioned combination of molecules at the low-grade dysplasia stage are defined as gastric cancer very early cells, and the stage at which gastric cancer very early cells appear is defined as the gastric cancer very early stage. This stage is an important point at which gastric precancerous lesions such as low-grade dysplasia transform into gastric cancer, that is, the starting point of carcinogenesis. Evaluating the expression level of the combination of gastric cancer very early cell marker molecules and quantifying the content of gastric cancer very early cells in a sample provides an important basis for assessing the risk of progression from low-grade dysplasia to gastric cancer and for diagnosing gastric cancer very early.

[0006] In order to improve the specificity of the marker molecule, the present invention further prepares a related monoclonal antibody, so that the expression of the marker molecule can be more specifically detected in clinical samples. Based on the above antibody, the present invention develops and develops a reagent kit for detecting and evaluating the content of very early stage gastric cancer cells in clinical tissue samples, and also develops a system for accurately determining the risk of very early stage gastric cancer. This is expected to provide effective basis for patients with digestive system tumors such as gastric cancer to take relevant treatment measures or decisions, and has good prospects for clinical application.

[0007] According to one aspect, the present invention provides an application of a reagent for detecting the expression level of a combination of markers in the preparation of a product for determining ultra-early stage gastric cancer diagnosis, in which the components of the combination of markers include KLK10, KRT7 and LAMC2, and the combination methods include 1) KLK10 and LAMC2, 2) KRT7 and LAMC2, and 3) KRT7, KLK10 and LAMC2.

[0008] In another aspect of the invention, reagents are provided which contain independently produced monoclonal antibodies to KLK10 and LAMC2. Among them, the gene locus sequence of the KLK10 monoclonal antibody is AEAALLPQNDTRLDPEAYGSPCARGSQPWQVSLFNGLSFHCAGVLVDQSWVLTAAHCGNK PLWARVGDDHLLLLQGEQLRRTTRSVVHPKYHQGSGPILPRRTDEHDLMLLKLARPVVLG PRVRALQLPYRCAQPGDQCQVAGWGTTAARRVKYNKGLTCSSITILSPKECEVFYPGVVT NNMICAGLDRGQDPCQSDSGGPLVCDETLQGILSWGVYPCGSAQHPAVYTQICKYMSWINKVIRSN (SEQ ID NO: 1). The gene locus sequence of the LAMC2 monoclonal antibody is >sp|Q13753|22-1193 TSRREVCDCNGKSRQCIFDRELHRQTGNGFRCLNCNDNTDGIHCEKCKNGFYRHRERDRC LPCNCNSKGSLSARCDNSGRCSCPKPGVTGARCDRCLLPGFHMLTDAGCTQDQRLLDSKCDC DPAGIAGPCDAGRCVCKPAVTGERCDRCRSGYYNLDGGNPEGCTQCFCYGHSASCRSSAE YSVHKITSTFHQDVDGWKAVQRNGSPAKLQWSQRHQDVFSSAQRLDPVYFVAPAKFLGNQ QVSYGQSLSFDYRVDRGGRHPSAHDVILEGAGLRITAPLMPLGKTLPCGLTKTYTFRLNE HPSNNWSPQLSYFEYRRLLRNLTALRIRATYGEYSTGYIDNVTLISARPVSGAPAPWVEQ CICPVGYKGQFCQDCASGYKRDSARLGPFGTCIPCNCQGGGACDPDTGDCYSGDENPDIE CADCPIGFYNDPHDPRSCKPCPCHNGFSCSVMPETEEVVCNNCPPGVTGARCELCADGYF GDPFGEHGPVRPCQPCQCNNNVDPSASGNCDRLTGRCLKCIHNTAGIYCDQCKAGYFGDP LAPNPADKCRACNCNPMGSEPVGCRSDGTCVCKPGFGGPNCEHGAFSCPACYNQVKIQMD QFMQQLQRMEALISKAQGGDGVVPDTELEGRMQQAEQALQDILRDAQISEGASRSLGLQL AKVRSQENSYQSRLDDLKMTVERVRALGSQYQNRVRDTHRLITQMQLSLAESEASLGNTN IPASDHYVGPNGFKSLAQEATRLAESHVESASNMEQLTRETEDYSKQALSLVRKALHEGV GSGSGSPDGAVVQGLVEKLEKTKSLAQQLTREATQAEIEADRSYQHSLRLLDSVSRLQGV SDQSFQVEEAKRIKQKADSLSSLVTRHMDEFKRTQKNLGNWKEEAQQLLQNGKSGREKSD QLLSRANLAKSRAQEALSMGNATFYEVESILKNLREFDLQVDNRKAEAEEAMKRLSYISQ KVSDASDKTQQAERALGSAADAQRAKNGAGEALEISSEIEQEIGSLNLEANVTADGALA MEKGLASLKSEMREVEGELERKELEFDTNMDAVQMVITEAQKVDTRAKNAGVTIQDTLNT LDGLLHLMDQPLSVDEEGLVLLEQKLSRAKTQINSQLRPMMSELEERARQQRGHLHLLET SIDGILADVKNLENIRDNLPPGCYNTQALEQQ (sequence number 2).

[0009] In another aspect of the present invention, an immunohistochemical detection kit is provided for determining the content of very early stage gastric cancer cells by immunostaining the expression levels of one or more combinations of three protein molecules, KLK10, LAMC2, and KRT7, thereby assisting in the diagnosis of very early stage gastric cancer.

[0010] In one aspect of the present invention, a combination of three molecules, KLK10, LAMC2 and KRT7, is provided as a characteristic of very early stage gastric cancer cells, and the combination is used to determine the risk of progression from low-grade dysplasia to gastric cancer.

[0011] Another aspect of the invention provides that a combination of three molecules, KLK10, LAMC2 and KRT7, can be used to characterize the progression from precancerous lesions to early cancer in tissues such as the pancreas, intestine and esophagus, and to identify early stage pancreatic, intestinal and esophageal cancer.

[0012] In yet another aspect of the present invention, the expression levels of three molecules, KLK10, LAMC2 and KRT7, are correlated with the survival risk of post-operative recurrence of gastric cancer, and this correlation is used to determine the risk of post-operative recurrence of gastric cancer.

[0013] In yet another aspect of the present invention, there is provided a detection kit, which can be used not only to determine the content of early stage cells of gastric precancerous lesions and early cancer cells in a test tissue by immunohistochemically staining the above protein molecules to obtain their expression status in the test tissue of the stomach, but also to detect the expression status of the above protein molecules in the blood by enzyme-linked immunosorbent assay (ELISA).

[0014] In yet another aspect of the present invention, a system and method for determining precancerous lesions in the stomach, early stage gastric cancer, early stage pancreatic cancer, early stage intestinal cancer, and early stage esophageal cancer, and / or determining the risk of postoperative recurrence of gastric cancer, are provided. The system determines the risk of a subject suffering from precancerous lesions in the stomach and / or gastric cancer, and / or the risk of postoperative recurrence of gastric cancer, by determining the number of precancerous lesion cells and early stage cancer cells in the stomach tissue based on the expression status of cell target proteins in the tissue or blood. The system further determines the risk of a subject suffering from other tumors of the digestive system, such as intestinal cancer, esophageal cancer, and pancreatic cancer, based on the expression status of cell target proteins in the tissue or blood of the subject.

[0015] According to one embodiment of the present invention, the above system further comprises: A detection kit for obtaining the expression status in a test tissue by individually immunohistochemically staining the expression levels of gastric cancer very early cell markers KLK10, LAMC2 and KRT7, and / or for detecting the content of the gastric cancer very early cell markers in a blood sample of a test patient by enzyme-linked immunosorbent assay; and a gastric cancer very early cell counting and stratification device for determining the proportional score and stratification degree (Grade) of positive cells for gastric cancer very early cell markers KLK10, LAMC2 and KRT7 in the test tissue sample, and / or for calculating the average value to determine the total expression level of KLK10, LAMC2 and KRT7 in the serum of the blood test sample.

[0016] In a further aspect of the present invention, the above system determines a patient's risk index for progression of gastric cancer and / or a risk index for postoperative recurrence of gastric cancer by performing a stratification process of expression levels including negative (occupancy ratio=0%, Grade 0), low (occupancy ratio<5%, Grade 1), medium (5%<occupancy ratio<30%, Grade 2), and high (occupancy ratio>30%, Grade 3) based on the proportion of very early stage gastric cancer cells to the total cell number in the entire test tissue; and / or determines a risk index for esophageal cancer, pancreatic cancer, and intestinal cancer using the above-mentioned stratification process method based on the expression levels of gastric cancer very early stage cell marker molecules in esophageal, pancreatic, and intestinal tissues; and / or determines a risk index for the test patient for developing a digestive system tumor using the total expression level in serum of the marker molecules for gastric cancer very early stage cells.

[0017] In a further aspect of the present invention, there is provided an application of a reagent for obtaining the expression status in a test tissue and / or blood by measuring the expression levels of three types of very early gastric cancer cell markers, KLK10, LAMC2 and KRT7, in the preparation of a composition for identifying early gastric precancerous lesions and / or early gastric cancer and other early gastrointestinal tumors. [Brief description of the drawings]

[0018] [Figure 1] FIG. 1 is a principle diagram of a system for assessing the progression risk of gastric precancerous lesions and determining the risk of very early gastric cancer based on a combination of molecular marker monoclonal antibodies in one embodiment of the present invention. [Diagram 2] 2 is a box plot based on the expression of a combination of gastric cancer ultra-early cell marker molecules in one embodiment of the present invention, showing the expression status of the marker molecules in patient groups with different outcomes (the group of patients with low-grade dysplasia who progressed to gastric cancer, abbreviated as the progression group, the group of patients with low-grade dysplasia who regressed to non-low-grade dysplasia, abbreviated as the regression group, and the group who maintained low-grade dysplasia, abbreviated as the maintenance group). * indicates p-value ≦ 0.05. [Diagram 3]FIG. 3 is a ROC curve diagram showing the classification of patients into a progression group and a regression group using a combination of gastric cancer very early cell marker molecules for very early gastric cancer cells based on the present invention. [Figure 4A] FIG. 4A shows the association of the overall predictive performance of combinations of gastric cancer very early cell marker molecules for very early gastric cancer cells with the time to progression from low-grade dysplasia to gastric cancer. [Figure 4B] Figure 4B shows the relationship between the predictive performance and progression time of combinations of very early gastric cancer cell marker molecules for very early gastric cancer cells, grouped according to Helicobacter pylori infection status, for the risk of cancer progression in Helicobacter pylori-positive and -negative status. [Diagram 5] Figure 5 shows the association between combinations of very early gastric cancer cell marker molecules, clinicopathological parameters, and the risk of progression from low-grade dysplasia to gastric cancer, using the COX proportional hazards model. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0019] FIG. 1 is a principle diagram of a system for evaluating the risk of developing stomach cancer and for very early diagnosis based on a combination of very early cell markers for stomach cancer in one embodiment of the present invention.

[0020] Specifically, in the first aspect of the present invention, a detection kit based on three types of molecules is provided. The kit includes monoclonal antibodies for detecting the expression levels of KLK10, LAMC2 and KRT7 molecules, and further includes a blank solution, a diluent and an antigen activation solution. In one preferred embodiment of the present invention, the monoclonal antibody reagent is an antibody for immunohistochemical detection method, specifically as shown in Table 1. In another embodiment of the present invention, the monoclonal antibody reagent may be an antibody for Western Blot or ELISA detection method.

[0021] [Table 1]

[0022] In a second aspect of the present invention, there is provided a method for immunohistochemical detection of the expression levels of the above three molecules, KLK10, LAMC2 and KRT7, in gastric tissue. In an embodiment based on the measurement method of the present invention, in addition to the above reagents contained in the kit, the following reagents can be prepared or purchased by the user himself / herself. (1) Distilled or deionized water, (2) 3% H2O2, (3) xylene, (4) 75%, 85%, 95% alcohol and absolute ethanol; (5) 10 mM TBS solution (pH 7.2-7.4): Add 1.21 g of trishydroxymethylaminomethane, 7.6 g of sodium chloride, and 800 mL of distilled water, adjust the pH value of concentrated hydrochloric acid to 7.2-7.4, and finally make the volume constant to 1000 mL. (6) 10 mM, pH 6.0 citrate buffer: add 0.38 g of citric acid, 2.45 g of sodium citrate, and 900 mL of distilled water, adjust the pH of concentrated hydrochloric acid to 6.0, and finally make the volume to 1000 mL. (7) Hematoxylin solution, (8) Neutral resin. EXAMPLES

[0023] In order to verify the value of this invention in terms of the risk of developing gastric cancer in patients with low-grade dysplasia of the stomach, the diagnosis of digestive system tumors such as ultra-early gastric cancer, and prediction of the risk of gastric cancer recurrence, we have conducted a multifaceted verification of retrospective sequential cases collected clinically from multiple centers.

[0024] Application of a combination of very early gastric cancer cell markers in determining the risk of very early gastric cancer

[0025] Example 1 Analysis of grouping status and clinical characteristics of marker-validated patient groups

[0026] First, the inventors retrospectively selected a total of 324 consecutive cohort patients with low-grade dysplasia from three independent medical centers: Peking Union Hospital, Wangjing Hospital of the China Academy of Traditional Chinese Medicine, and Anhui Gejishan Hospital. The criteria for patient selection and grouping were as follows: 1) There were two or more records of gastric endoscopic examinations, 2) The baseline diagnosis was low-grade intraepithelial neoplasia, and 3) The patients were free of concomitant diseases such as gastric cancer, gastric ulcer, and other tumors. Based on the patients' final endoscopic diagnosis, the patients were divided into three groups: progressive (final pathology was gastric cancer or high-grade intraepithelial neoplasia), persistent (final pathology was low-grade intraepithelial neoplasia), and regressed (final pathology was intestinal metaplasia or atrophic gastritis, etc.). The breakdown was 107 cases in the progressive group, 41 cases in the persistent group, and 175 cases in the regressed group, with an average follow-up monitoring period of 18 months (range, 3-80 months).

[0027] Analysis of the baseline clinical characteristics of patients in each group showed that: 1) overall, the mean age of patients in the group was 59 years, the sex ratio was 1.59, the proportion of Helicobacter pylori infection was 0.28, the mean pathology record was 2.2 times, and there was no clear correlation between each clinical indicator; 2) among each group, the mean age of the progression group, the maintenance group, and the regression group was 63, 55, and 56 years, respectively, the sex ratio of the men and women was 2.29, 1.92, and 1.24, respectively, the proportion of the Helicobacter pylori infection was 0.21, 0.27, and 0.33, respectively, the mean follow-up period was 15.7 months, 15.9 months, and 18.9 months, and in each center, the number of cases in center 1, center 2, and center 3 was 110, 114, and 100, respectively, the mean age was 53, 56, and 63, respectively, and the sex ratio of the men and women was 2.24, 1.71, and 1.04, respectively. The proportion of patients with Helicobacter pylori infection was found to be 0.33, 0.21, and 0.32, with mean follow-up periods of 17.2, 21, and 16.5 months.

[0028] Detection of very early combined marker expression in gastric cancer First, the expression of the combined markers of three proteins KLK10, LAMC2, and KRT7 in 324 pathological specimens was obtained using an immunohistochemistry detection kit (20) based on the present invention. The kit uses immunohistochemistry (IHC) to compare the expression levels of the combined markers. The paraffin-embedded surgical specimens are fixed using 10% formalin buffer. The tissue sections are 4 micrometers per piece. The kit in this example includes the following: (1) Reagent A: sealing solution, 10% goat serum; (2) Reagent B: A pre-diluted, ready-to-use anti-KLK10 primary antibody; (3) Reagent C: A pre-diluted, ready-to-use anti-LAMC2 primary antibody; (4) Reagent D: Pre-diluted, ready-to-use anti-KRT7 primary antibody; (4) Reagent G: goat anti-biotin secondary antibody, (5) Reagent H: HRP labeled with streptavidin, (6) Reagent I: 20x concentrated DAB substrate solution; (7) Reagent J: 20x concentrated DAB substrate buffer solution, (8) Reagent K: 20x concentrated DAB color-developing solution.

[0029] In addition to the above reagents included in the kit, prepare the following reagents yourself: (1) Distilled or deionized water, (2) 3% H2O2, (3) xylene, (4) 75%, 85%, 95% alcohol and absolute ethanol; (5) 10 mM TBS solution (pH 7.2-7.4): Add 1.21 g of trishydroxymethylaminomethane, 7.6 g of sodium chloride, and 800 mL of distilled water, adjust the pH value of concentrated hydrochloric acid to 7.2-7.4, and finally make the volume constant to 1000 mL. (6) 10 mM, pH 6.0 citrate buffer: add 0.38 g of citric acid, 2.45 g of sodium citrate, and 900 mL of distilled water, adjust the pH of concentrated hydrochloric acid to 6.0, and finally make the volume to 1000 mL. (7) Hematoxylin solution, (8) Neutral resin.

[0030] The above kit was used to detect the expression of the combination markers in pancreatic cancer tissues. (1) Tissue embedding: fix the pancreatic cancer tissue specimen in 10% neutral formalin for 2 hours, wash repeatedly with running water to remove the fixative, place the specimen in 75% alcohol overnight, and then dehydrate it stepwise using alcohol: 75% alcohol for 1 hour, 85% alcohol for 1 hour, 95% alcohol for 1 hour, and absolute ethanol twice for 1.5 hours each. Then, immerse in xylene for 1.5 hours, embed in paraffin in a 60°C dryer for 1 hour, cool, and store at 4°C for preparation. (2) Paraffin sections: Prepare the paraffin block, adjust the slicer (SLEE Paraffin Slicer CUT5062) to set the thickness of the sections to 3-4 μm, slice continuously, float on 60°C warm water to open, and spread flat on a slide coated with cationic resin. (3) Baking the sections: Place the untreated sections on a section rack and bake in a 60°C incubator for at least 1 hour. (4) Deparaffinization: Place the sections in a container of xylene and deparaffinize three times for 10 minutes each time (i.e., xylene I, II, and III). (5) Hydration: Hydrate the sections in alcohol. Wash in absolute ethanol for 5 minutes, 95% ethanol twice (2 minutes each time), 85% ethanol for 2 minutes, 75% ethanol for 2 minutes, and distilled water for 1 minute. (6) Antigen retrieval: Add 1000 ml of citrate buffer to the autoclave, immerse the section rack with the sections in the buffer, and activate at high temperature and high pressure for 2 minutes and 45 seconds, then wash with TBS three times for 2 minutes each time. (7) Add 3% H2O2 drops onto the sections, leave them at room temperature for 15 minutes, and wash them with TBS three times for 2 minutes each time. (8) Mounting: Add a drop of Reagent A onto the section to completely cover the tissue section, incubate at room temperature for 10 minutes, and then blot the liquid. No washing is required. (9) Add primary antibody: Add drops of Reagent B (anti-KLK10 primary antibody), Reagent C (anti-LAMC2 primary antibody), and Reagent D (anti-KRT7 primary antibody) to different sections respectively to completely cover the tissue sections, and incubate in a humidified box at 37°C for 2 hours or at 4°C overnight. (10) Washing: Wash with TBS-T (3 x 5 min). (11) Add secondary antibody: completely cover the tissue section with Reagent G (dropwise adding biotin secondary antibody) and incubate in a humidified box at 37°C for 30 minutes. (12) Washing: Wash with TBS three times, for 5 minutes each time. (13) Add HRP-SA: Add a drop of Reagent H (HRP labeled with streptavidin) to completely cover the tissue section, and incubate in a humidified box at 37°C for 30 minutes. (14) Washing: Wash with TBS three times, for 5 minutes each time. (15) Preparation of DAB color developing solution: This must be prepared immediately before use. For example, to stain one section, add 2.5 ul of reagent I to 50 ul of distilled water and mix evenly, then add 2.5 ul of reagent J and 2.5 ul of reagent K to the above liquid and mix evenly. (16) Color development: Add a drop of the above DAB developing solution onto the section to completely cover the tissue section, observe the color development under a microscope, and wash with distilled water to stop the color development. (17) Re-staining: Re-stain with hematoxylin for 3 min, followed by differentiation with hydrochloric acid and alcohol. (18) Mounting of sections: Immerse in 75% alcohol for 2 minutes, 85% alcohol for 2 minutes, 95% alcohol for 2 minutes, absolute ethanol for 2 minutes, then immerse in xylene for 15 minutes, replace the xylene and soak for an additional 15 minutes, and mount the sections in neutral resin. (19) Interpretation of results: Observe the stained pancreatic cancer tissue sections under a microscope, stain positive results as brown particles, and randomly select five high-power fields (10*40) to count the number of positive cells. The percentages of positive cell counts are judged as 0%, 1-5%, 6-30%, and 31-100%, respectively, as 0, 1, 2, and 3 points. The staining intensity of positive cells in one section is judged as 0, 1, 2, and 3 points depending on whether they are unstained, light yellow, brown, or brownish brown, respectively.

[0031] Prediction of the risk of gastric cancer progression in low-grade dysplasia by combinations of very early gastric cancer cell markers The present inventors evaluated the ability of ultra-early cell markers for gastric cancer to predict the risk of cancer progression in gastric low-grade dysplasia from three aspects.

[0032] First, the inventors evaluated the overall distribution of marker expression levels in the three different groups. By quantifying the markers into four stages, negative (0), weakly positive (1), positive (2) and strongly positive (3), the inventors found that the expression levels of the marker molecules in the progression group were all significantly higher than those in the regression group, regardless of whether it was the overall situation or each independent center (Figure 2, p<0.01), indicating that the markers have value in classifying the progression risk of low-grade dysplasia.

[0033] Furthermore, the inventors evaluated the predictive performance of the markers for the progression risk of low-grade dysplasia and the diagnostic performance of very early gastric cancer. By creating an ROC curve (Figure 3) and comparing it with existing clinical pathological indicators (age, sex, Helicobacter pylori infection, etc.), the inventors determined that the predictive AUC value of the markers for the progression risk of low-grade dysplasia (and very early gastric cancer) was 0.87, and the overall prediction accuracy was 84%. All of the above values ​​were significantly superior to conventional clinical indicators such as patient age, sex, and Hp infection status (p<0.001), further verifying that the marker molecules have the ability to predict the cancer risk of low-grade dysplasia and determine the risk of very early gastric cancer.

[0034] Furthermore, the inventors used the COX proportional hazards model to evaluate the association between marker expression and the risk of progression of low-grade dysplasia, and also evaluated the binding status of this association with clinical pathological parameters. Both single-factor and multi-factor analyses revealed that high marker expression was an important risk factor for the progression of low-grade dysplasia to cancer (p<0.05). Furthermore, the predictive performance of the markers for the risk of progression to cancer was independent of clinical indicators, but neither gender nor Helicobacter pylori infection was a significant independent risk factor (Figure 5).

[0035] Finally, the inventors evaluated the relevance of the predictive performance of the markers with time progression by detecting the expression of the markers at different time points of the progression of low-grade dysplasia (Figures 4A and 4B). In the entire patient group, the predictive performance of the markers for the risk of cancer progression was closely related to the duration of time progression, with the predictive accuracy increasing significantly to 88% 12 months before cancer onset and reaching 96% at 3 to 6 months before cancer onset, indicating that the ultra-early gastric cancer markers can effectively advance the period of early gastric cancer diagnosis by 6 to 12 months. By grouping according to the infection status of Helicobacter pylori, it was determined that the period that the markers can advance in the Helicobacter pylori-negative group was an average of 12 months, with an accuracy of 93%, indicating that the markers can further extend the period of early gastric cancer diagnosis in the Helicobacter pylori-negative group. For very early stage gastric cancer within 3 months, the predictive accuracy of the marker molecules in the entire sample reached 97%. In the Helicobacter pylori-positive group, 100% of very early stage gastric cancer patients were predicted by selecting the marker molecules, demonstrating the diagnostic potential of the marker for very early stage gastric cancer.

[0036] References: 1. Zhang P, Yang M, Zhang Y, et al.Dissecting the single-cell transcriptome network underlying gastric premalignant lesions and early gastric cancer.Cell Rep.2019;27(6):1934-1947.e5. 2. Li Zhou, Zhang Peng, Ultra-early cell marker for gastric cancer and early cell marker for gastric precancerous lesions, and their application in diagnostic kits. China Patent, ZL202080001970.7

Claims

1. A use of a reagent for detecting the expression level of a combination of gastric cancer very early cell marker molecules in a gastric tissue or serum sample from a subject in the preparation of a product for determining the risk of progression from gastric low-grade dysplasia to gastric cancer and / or for determining the risk of developing very early gastric cancer, The combination of the very early cell marker molecules of the very early cell gastric cancer is the following combination of the very early cell marker molecules of gastric cancer: 1) KLK10 and LAMC2, 2) KRT7 and LAMC2, 3) comprising one selected from KRT7, KLK10 and LAMC2; Purpose.

2. The use according to claim 1, wherein cells labeled with the combination of very early cell marker molecules of very early cell gastric cancer in a low-grade dysplasia sample are defined as very early gastric cancer cells, and the stage at which very early gastric cancer cells appear is defined as the very early gastric cancer stage, and the content of very early gastric cancer cells in a sample is quantified by evaluating the expression level of the combination of gastric cancer very early cell marker molecules.

3. The reagent comprises KLK10 and LAMC2 monoclonal antibodies, wherein the gene locus sequence of the KLK10 monoclonal antibody is: AEAALLPQNDTRLDPEAYGSPCARGSQPWQVSLFNGLSFHCAGVLVDQSWVLTAAHCGNK PLWARVGDDHLLLLQGEQLRRTTRSVVHPKYHQGSGPILPRRTDEHDLMLLKLARPVVLG PRVRALQLPYRCAQPGDQCQVAGWGTTAARRVKYNKGLTCSSITILSPKECEVFYPGVVT NNMICAGLDRGQDPCQSDSGGPLVCDETLQGILSWGVYPCGSAQHPAVYTQICKYMSWINKVIRSN; The gene locus sequence of the LAMC2 monoclonal antibody is: >sp|Q13753|22-1193 TSRREVCDCNGKSRQCIFDRELHRQTGNGFRCLNCNDNTDGIHCEKCKNGFYRHRERDRC LPCNCNSKGSLSARCDNSGRCSCPKPGVTGARCDRCLPGHMLTDAGCTQDQRLLDSKCDC DPAGIAGPCDAGRCVCKPAVTGERCDRCRSGYYNLDGGNPEGCTQCFCYGHSASCRSSAE YSVHKITSTFHQDVDGWKAVQRNGSPAKLQWSQRHQDVFSSAQRLDPVYFVAPAKFLGNQ QVSYGQSLSFDYRVDRGGRHPSAHDVILEGAGLRITAPLMPLGKTLPCGLTKTYTFRLNE HPSNNWSPQLSYFEYRRLLRNLTALRIRATYGEYSTGYIDNVTLISARPVSGAPAPWVEQ CICPVGYKGQFCQDCASGYKRDSARLGPFGTCIPCNCQGGGACDPDTGDCYSGDENPDIE CADCPIGFYNDPHDPRSCKPCPCHNGFSCSVMPETEEVVCNNCPPGVTGARCELCADGYF GDPFGEHGPVRPCQPCQCNNNVDPSASGNCDRLTGRCLKCIHNTAGIYCDQCKAGYFGDP LAPNPADKCRACNCNPMGSEPVGCRSDGTCVCKPGFGGPNCEHGAFSCPACYNQVKIQMD QFMQQLQRMEALISKAQGGDGVVPDTELEGRMQQAEQALQDILRDAQISEGASRSLGLQL AKVRSQENSYQSRLDDLKMTVERVRALGSQYQNRVRDTHRLITQMQLSLAESEASLGNTN IPASDHYVGPNGFKSLAQEATRLAESHVESASNMEQLTRETEDYSKQALSLVRKALHEGV GSGSGSPDGAVVQGLVEKLEKTKSLAQQLTREATQAEIEADRSYQHSLRLLDSVSRLQGV SDQSFQVEEAKRIKQKADSLSSLVTRHMDEFKRTQKNLGNWKEEAQQLLQNGKSGREKSD QLLSRANLAKSRAQEALSMGNATFYEVESILKNLREFDLQVDNRKAEAEEAMKRLSYISQ KVSDASDKTQQAERALGSAAADAQRAKNGAGEALEISSEIEQEIGSLNLEANVTADGALA MEKGLASLKSEMREVEGELERKELEFDTNMDAVQMVITEAQKVDTRAKNAGVTIQDTLNT LDGLLHLMDQPLSVDEEGLVLLEQKLSRAKTQINSQLRPMMSELEERARQQRGHLHLLET SIDGILADVKNLENIRDNLPPGCYNTQALEQQ, 3. Use according to claim 1 or 2.

4. In the detection kit, The detection kit is used to obtain the expression status of the combination of gastric cancer very early cell marker molecules in a gastric tissue test sample by immunohistochemical staining of the combination of gastric cancer very early cell marker molecules, and / or to detect the expression status of the combination of gastric cancer very early cell marker molecules in a blood sample by enzyme-linked immunosorbent assay; Among them, The combination of the gastric cancer very early cell marker molecules is the following combination of gastric cancer very early cell marker molecules: 1) KLK10 and LAMC2, 2) KRT7 and LAMC2, 3) comprising one selected from KRT7, KLK10 and LAMC2; Detection kit.

5. The detection kit includes KLK10 and LAMC2 monoclonal antibodies, of which the gene locus sequence of the KLK10 monoclonal antibody is: AEAALLPQNDTRLDPEAYGSPCARGSQPWQVSLFNGLSFHCAGVLVDQSWVLTAAHCGNK PLWARVGDDHLLLLQGEQLRRTTRSVVHPKYHQGSGPILPRRTDEHDLMLLKLARPVVLG PRVRALQLPYRCAQPGDQCQVAGWGTTAARRVKYNKGLTCSSITILSPKECEVFYPGVVT NNMICAGLDRGQDPCQSDSGGPLVCDETLQGILSWGVYPCGSAQHPAVYTQICKYMSWINKVIRSN; Among them, the gene locus sequence of the LAMC2 monoclonal antibody is: >sp|Q13753|22-1193 TSRREVCDCNGKSRQCIFDRELHRQTGNGFRCLNCNDNTDGIHCEKCKNGFYRHRERDRC LPCNCNSKGSLSARCDNSGRCSCPKPGVTGARCDRCLPGHMLTDAGCTQDQRLLDSKCDC DPAGIAGPCDAGRCVCKPAVTGERCDRCRSGYYNLDGGNPEGCTQCFCYGHSASCRSSAE YSVHKITSTFHQDVDGWKAVQRNGSPAKLQWSQRHQDVFSSAQRLDPVYFVAPAKFLGNQ QVSYGQSLSFDYRVDRGGRHPSAHDVILEGAGLRITAPLMPLGKTLPCGLTKTYTFRLNE HPSNWSPQLSYFEYRRLLRNLTALRIRATYGEYSTGYIDNVTLISARPVSGAPAPWVEQ CICPVGYKGQFCQDCASGYKRDSARLGPFGTCIPNCQGGGACDPDTGDCYSGDENPDIE CADCPIGFYNDPHDPRSCKPCPCHNGFSCSVMPETEEVVCNNCPPGVTGARCELCADGYF GDPFGEHGPVRPCQPCQCNNNVDPSASGNCDRLTGRCLKCIHNTAGIYCDQCKAGYFGDP LAPNPADKCRACNCNPMGSEPVGCRSDGTCVCKPGFGGPNCEHGAFSCPACYNQVKIQMD QFMQQLQRMEALISKAQGGDGVVPDTELEGRMQQAEQALQDILRDAQISEGASRSLGLQL AKVRSQENSYQSRLDDLKMTVERVRALGSQYQNRVRDTHRLITQMQLSLAESEASLGNTN IPASDHYVGPNGFKSLAQEATRLAESHVESASNMEQLTRETEDDYSKQALSLVRKALHEGV GSGSGSPDGAVVQGLVEKLEKTKSLAQQLTREATQAEIEADRSYQHSLRLLDSVSRLQGV SDQSFQVEEAKRIKQKADSLSSLVTRHMDEFKRTQKNLGNWKEEAQQLLQNGKSGREKSD QLLSRANLAKSRAQEALSMGNATFYEVESILKNLREFDLQVDNRKAEAEEAMKRLSYISQ KVSDASDKTQQAERALGSAAAADAQRAKNGAGEALEISSEIEQEIGSLNLEANVTADGALA MEKGLASLKSEMREVEGELERKELEFDTNMDAVQMVITEAQKVDTRAKNAGVTIQDTLNT LDGLLHLMDQPLSVDEEGLVLLEQKLSRAKTQINSQLRPMMSELEERARQQRGHLHLLET SIDGILADVKNLENIRDNLPPGCYNTQALEQQ, The detection kit according to claim 4.

6. A system for determining risk of a lesion, the lesion being one of a precancerous lesion of the stomach, an early stage gastric cancer, and a postoperative recurrence of gastric cancer; Among them, The system determines the number of gastric precancerous lesion cells and / or early cancer cells in a gastric tissue test sample based on the expression status of a combination of gastric cancer very early cell marker molecules in the gastric tissue test sample from the subject, thereby determining whether the subject is suffering from a precancerous lesion and / or is at risk of postoperative recurrence of gastric cancer; The above system is A detection kit (20) for obtaining the expression status in a gastric tissue test sample by immunohistochemical staining of the expression level (11) of the combination of gastric cancer very early cell marker molecules, and / or for detecting the content (11) of the combination of gastric cancer very early cell marker molecules in a blood sample of a test patient by enzyme-linked immunosorbent assay; a counting and stratification device (30) for determining the proportional score and stratification degree (31) of positive cells of said combination of gastric cancer very early cell marker molecules in a gastric tissue test sample, and / or for calculating an average value to determine the overall expression level of said combination of gastric cancer very early cell marker molecules in the serum of a blood test sample, Among them, The combination of the gastric cancer very early cell marker molecules is the following combination of gastric cancer very early cell marker molecules: 1) KLK10 and LAMC2, 2) KRT7 and LAMC2, 3) comprising one selected from KRT7, KLK10 and LAMC2; system.

7. The counting and stratification device (30) performs a stratification process of expression levels including negative (occupancy ratio=0%, Grade 0), low (occupancy ratio<5%, Grade 1), medium (5%<occupancy ratio<30%, Grade 2), and high (occupancy ratio>30%, Grade 3) based on the proportion of gastric cancer very early stage cells in the total cell number of the entire tissue test sample, thereby determining a patient's risk index of gastric cancer progression and / or a risk index of gastric cancer postoperative recurrence, and / or determining a risk index of the test patient suffering from a digestive system tumor by using the total expression level of gastric cancer very early stage cell marker molecules in serum. The system of claim 6.

8. 1. A system for determining risk of a pathology, the pathology being one of early stage pancreatic cancer, early stage intestinal cancer, and early stage esophageal cancer; Among them, The system determines a subject's risk of developing intestinal cancer, esophageal cancer, pancreatic cancer, or other tumors of the digestive system based on the expression status of cellular target proteins in a tissue or blood sample from the subject; The above system is a detection kit (20) for detecting the content of the combination of gastric cancer very early cell marker molecules in a blood sample by enzyme-linked immunosorbent assay; a counting and stratification device (30) for calculating an average value to determine the overall expression level (33) of said combination of gastric cancer very early cell marker molecules in the serum of the blood sample; Among them, The combination of the gastric cancer very early cell marker molecules is the following combination of gastric cancer very early cell marker molecules: 1) KLK10 and LAMC2, 2) KRT7 and LAMC2, 3) comprising one selected from KRT7, KLK10 and LAMC2; system.

9. The counting and stratification device (30) determines a risk index for the subject to suffer from esophageal cancer, pancreatic cancer and intestinal cancer based on the expression level of the very early stage gastric cancer cell marker molecule in the subject's esophageal, pancreatic and / or intestinal tissue or blood sample. The system of claim 8.

Citation Information

Patent Citations

  • Gastric cancer extremely-early cell marker, gastric cancer precancerous lesion early cell marker and application of markers in diagnostic kits

    CN111781356A

  • Gastric cancer inspection method and inspection kit

    JP2014238264A

  • ERCC1 and other markers for stratification of patients with non-small cell lung cancer

    JP2019513982A

  • Use of laminin 2 for diagnosing hepatocellular carcinoma and pancreatic cancer

    JP2021060418A